Floatz logo

5,5'-DINITROSALICIL

NSCLC Stage IV

Wuhan YZY Biopharma Co., Ltd.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the NSCLC Stage IV cohort.

Asset / SponsorPhaseRating
uv1
Vestre Viken Hospital Trust
Phase 2BB
ab-16b5
Alethia Biotherapeutics
Phase 2B
l19-il2
Maastricht Radiation Oncology
Phase 2CCC
Sagramostim
Vestre Viken Hospital Trust
Phase 2CCC
Zalifrelimab
Agenus Inc.
Phase 2CCC

View all 12 →

Same molecule, other indications

5,5'-DINITROSALICIL is also rated in:

Malignant AscitesDormant
BB
Indicative ·
64 / 100
View asset →
Malignant Pleural EffusionsDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →